An Hotterbeekx

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8787436/publications.pdf

Version: 2024-02-01

44 papers	1,042 citations	535685 17 h-index	511568 30 g-index
45 all docs	45 docs citations	45 times ranked	1035 citing authors

#	Article	IF	Citations
1	Host Immunity Influences the Composition of Murine Gut Microbiota. Frontiers in Immunology, 2022, 13, 828016.	2.2	11
2	Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis. Journal of Clinical Medicine, 2022, 11, 1494.	1.0	2
3	Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients. Clinica Chimica Acta, 2022, 531, 4-11.	0.5	8
4	Identification of Potential Urinary Metabolite Biomarkers of Pseudomonas aeruginosa Ventilator-Associated Pneumonia. Biomarker Insights, 2022, 17, 117727192210991.	1.0	1
5	Immunoinformatics Design and Assessment of a Multiepitope Antigen (OvMCBL02) for Onchocerciasis Diagnosis and Monitoring. Diagnostics, 2022, 12, 1440.	1.3	4
6	Neuropathological Changes in Nakalanga Syndromeâ€"A Case Report. Pathogens, 2021, 10, 116.	1.2	2
7	Potential Parasitic Causes of Epilepsy in an Onchocerciasis Endemic Area in the Ituri Province, Democratic Republic of Congo. Pathogens, 2021, 10, 359.	1.2	3
8	Onchocerciasis Prevalence among Persons with Epilepsy in an Onchocerciasis Hypo-Endemic Area in the Democratic Republic of Congo: A Cross-Sectional Study. Pathogens, 2021, 10, 389.	1.2	1
9	Cytokines and Onchocerciasis-Associated Epilepsy, a Pilot Study and Review of the Literature. Pathogens, 2021, 10, 310.	1.2	2
10	The Secretome of Filarial Nematodes and Its Role in Host-Parasite Interactions and Pathogenicity in Onchocerciasis-Associated Epilepsy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 662766.	1.8	17
11	Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. European Journal of Cancer, 2021, 148, 328-339.	1.3	14
12	Serotonin Levels in the Serum of Persons with Onchocerciasis-Associated Epilepsy: A Case-Control Study. Pathogens, 2021, 10, 720.	1.2	3
13	No Evidence for the Involvement of Leiomodin-1 Antibodies in the Pathogenesis of Onchocerciasis-Associated Epilepsy. Pathogens, 2021, 10, 845.	1.2	16
14	A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity. JCI Insight, 2021, 6, .	2.3	23
15	Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation. PLoS Neglected Tropical Diseases, 2021, 15, e0008965.	1.3	55
16	Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with Onchocerca volvulus. Pathogens, 2021, 10, 21.	1.2	7
17	Risk Factors for Nodding Syndrome and Other Forms of Epilepsy in Northern Uganda: A Case-Control Study. Pathogens, 2021, 10, 1451.	1.2	9
18	Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis. Life, 2021, 11, 1284.	1.1	4

#	Article	IF	Citations
19	Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients. Cancers, 2021, 13, 5718.	1.7	10
20	Dried Blood Microsampling-Based Therapeutic Drug Monitoring of Antiepileptic Drugs in Children With Nodding Syndrome and Epilepsy in Uganda and the Democratic Republic of the Congo. Therapeutic Drug Monitoring, 2020, 42, 481-490.	1.0	12
21	Onchocerca volvulus is not detected in the cerebrospinal fluid of persons with onchocerciasis-associated epilepsy. International Journal of Infectious Diseases, 2020, 91, 119-123.	1.5	30
22	Ivermectin Treatment Response in Onchocerca Volvulus Infected Persons with Epilepsy: A Three-Country Short Cohort Study. Pathogens, 2020, 9, 617.	1.2	9
23	Comparison of Diagnostic Tests for Onchocerca volvulus in the Democratic Republic of Congo. Pathogens, 2020, 9, 435.	1.2	15
24	Urinary N-acetyltyramine-O,Î²-glucuronide in Persons with Onchocerciasis-Associated Epilepsy. Pathogens, 2020, 9, 191.	1.2	8
25	Single versus Multiple Dose Ivermectin Regimen in Onchocerciasis-Infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo. Pathogens, 2020, 9, 205.	1.2	16
26	Prevalence and incidence of nodding syndrome and other forms of epilepsy in onchocerciasis-endemic areas in northern Uganda after the implementation of onchocerciasis control measures. Infectious Diseases of Poverty, 2020, 9, 12.	1.5	52
27	Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: AÂrandomized proof-of-concept clinical trial. PLoS Neglected Tropical Diseases, 2020, 14, e0007966.	1.3	19
28	From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes. PLoS Neglected Tropical Diseases, 2019, 13, e0007407.	1.3	47
29	Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density. IBRO Reports, 2019, 6, S506.	0.3	8
30	Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?. Infectious Diseases of Poverty, 2019, 8, 77.	1.5	2
31	Neuroinflammation and Not Tauopathy Is a Predominant Pathological Signature of Nodding Syndrome. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1049-1058.	0.9	44
32	High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment. International Journal of Infectious Diseases, 2019, 79, 187-194.	1.5	41
33	Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density. PLoS Neglected Tropical Diseases, 2019, 13, e0007300.	1.3	47
34	Nodding Syndrome. Pediatric Infectious Disease Journal, 2019, 38, e313-e313.	1.1	0
35	Neurological manifestations in Onchocerca volvulus infection: A review. Brain Research Bulletin, 2019, 145, 39-44.	1.4	21
36	Onchocerciasis-Associated Epilepsy, an Additional Reason for Strengthening Onchocerciasis Elimination Programs. Trends in Parasitology, 2018, 34, 208-216.	1.5	71

#	Article	IF	Citations
37	Report of the first international workshop on onchocerciasis-associated epilepsy. Infectious Diseases of Poverty, 2018, 7, 23.	1.5	30
38	Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study. Infectious Diseases of Poverty, 2018, 7, 79.	1.5	19
39	High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo. Infectious Diseases of Poverty, 2018, 7, 68.	1.5	49
40	Histological examination of post-mortem brains of children with nodding syndrome. Annals of Translational Medicine, 2018, 6, 134-134.	0.7	7
41	In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp.. Frontiers in Cellular and Infection Microbiology, 2017, 7, 106.	1.8	193
42	Characterizing the in vitro biofilm phenotype of Staphylococcus epidermidis isolates from central venous catheters. Journal of Microbiological Methods, 2016, 127, 95-101.	0.7	18
43	The endotracheal tube microbiome associated with Pseudomonas aeruginosa or Staphylococcus epidermidis. Scientific Reports, 2016, 6, 36507.	1.6	51
44	Colistin-Resistant Acinetobacter baumannii Clinical Strains with Deficient Biofilm Formation. Antimicrobial Agents and Chemotherapy, 2016, 60, 1892-1895.	1.4	38